Resveratrol protects against Helicobacter pylori-associated gastritis by combating oxidative stress

International Journal of Molecular Sciences

Volumn 16, Issue 11, 2015, Pages 27757-27769

  Zhang, Xiaolin ^a   Jiang, Anmin ^b   Qi, Banghua ^a   Ma, Zhongyou ^a   Xiong, Youyi ^a   Dou, Jinfeng ^a   Wang, Jianfei ^a,c  

^a ANHUI SCIENCE AND TECHNOLOGY UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c Ministry of Agriculture Key Laboratory of Microbial Organic Fertilizer   (China)

Author keywords

Gastritis; HO 1; IL 8; INOS; Nrf2; Oxidative stress; Resveratrol

Indexed keywords

HEME OXYGENASE 1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; LIPID PEROXIDE; MESSENGER RNA; MYELOPEROXIDASE; RESVERATROL; THIOBARBITURIC ACID; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH BIOPSY; WESTERN BLOTTING; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GASTRITIS; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHOSPHORYLATION; STOMACH MUCOSA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEME OXYGENASE-1; INTERLEUKIN-8; LIPID PEROXIDES; MALE; MICE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PEROXIDASE; PHOSPHORYLATION; STILBENES;

EID: 84947784590     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161126061     Document Type: Article

References (46)

1. Blaser, M.J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J. Infect. Dis. 1990, 161, 626-633. [CrossRef] [PubMed]
2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. J. Am. Med. Assoc. 1994, 272, 65-69.
3. Amagase, K.; Nakamura, E.; Endo, T.; Hayashi, S.; Hasumura, M.; Uneyama, H.; Torii, K.; Takeuchi, K. New frontiers in gut nutrient sensor research: Prophylactic effect of glutamine against Helicobacter pylori-induced gastric diseases in Mongolian gerbils. J. Pharmacol. Sci. 2010, 112, 25-32. [CrossRef] [PubMed]
4. Handa, O.; Naito, Y.; Yoshikawa, T. Helicobacter pylori: A ROS-inducing bacterial species in the stomach. Inflamm. Res. 2010, 59, 997-1003. [CrossRef] [PubMed]
5. Kaise, M.; Miwa, J.; Iihara, K.; Suzuki, N.; Oda, Y.; Ohta, Y. Helicobacter pylori stimulates inducible nitric oxide synthase in diverse topographical patterns in various gastroduodenal disorders. Dig. Dis. Sci. 2003, 48, 636-643. [CrossRef] [PubMed]
6. Rieder, G.; Hofmann, J.A.; Hatz, R.A.; Stolte, M.; Enders, G.A. Up-regulation of inducible nitric oxide synthase in Helicobacter pylori-associated gastritis may represent an increased risk factor to develop gastric carcinoma of the intestinal type. Int. J. Med. Microbiol. 2003, 293, 403-412. [CrossRef] [PubMed]
7. Kim, H.; Lim, J.W.; Kim, K.H. Helicobacter pylori-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: Mediation by nuclear factor-κB. Scand. J. Gastroenterol. 2001, 36, 706-716. [CrossRef] [PubMed]
8. Kim, H.; Seo, J.Y.; Kim, K.H. Inhibition of lipid peroxidation, NF-κB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig. Dis. Sci. 2000, 45, 621-628. [CrossRef] [PubMed]
9. Lim, J.W.; Kim, H.; Kim, K.H. NF-κB, inducible nitric oxide synthase and apoptosis by Helicobacter pylori infection. Free Radic. Biol. Med. 2001, 31, 355-366. [CrossRef]
10. Fu, S.; Ramanujam, K.S.; Wong, A.; Fantry, G.T.; Drachenberg, C.B.; James, S.P.; Meltzer, S.J.; Wilson, K.T. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999, 116, 1319-1329. [CrossRef]
11. Toyoda, T.; Tsukamoto, T.; Takasu, S.; Shi, L.; Hirano, N.; Ban, H.; Meltzer, S.J.; Wilson, K.T. Anti-inflammatory effects of caffeic acid phenethyl ester (CAPE), a nuclear factor-κB inhibitor, on Helicobacter pylori-induced gastritis in Mongolian gerbils. Int. J. Cancer 2009, 125, 1786-1795. [CrossRef] [PubMed]
12. Baeuerle, P.A.; Baltimore, D. NF-κB: Ten years after. Cell 1996, 87, 13-20. [CrossRef]
13. Thanos, D.; Maniatis, T. NF-κB: A lesson in family values. Cell 1995, 80, 529-532. [CrossRef]
14. Karin, M.; Greten, F.R. NF-κB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5, 749-759. [CrossRef] [PubMed]
15. Suzuki, M.; Miura, S.; Mori, M.; Kai, A.; Suzuki, H.; Fukumura, D.; Suematsu, M.; Tsuchiya, M. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994, 35, 1375-1378. [CrossRef] [PubMed]
16. Klebanoff, S.J. Myeloperoxidase: Friend and foe. J. Leukoc. Biol. 2005, 77, 598-625. [CrossRef] [PubMed]
17. Naito, Y.; Takagi, T.; Uchiyama, K.; Yoshikawa, T. Heme oxygenase-1: A novel therapeutic target for gastrointestinal diseases. J. Clin. Biochem. Nutr. 2011, 48, 126-133. [CrossRef] [PubMed]
18. Naito, Y.; Takagi, T.; Yoshikawa, T. Heme oxygenase-1: A new therapeutic target for inflammatory bowel disease. Aliment. Pharmacol Ther. 2004, 20 (Suppl. S1), 177-184. [CrossRef] [PubMed]
19. Motohashi, H.; Yamamoto, M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 2004, 10, 549-557. [CrossRef] [PubMed]
20. Surh, Y.J.; Kundu, J.K.; Na, H.K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008, 74, 1526-1539. [CrossRef] [PubMed]
21. Alam, J.; Cook, J.L. Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway. Curr. Pharm. Des. 2003, 9, 2499-2511. [CrossRef] [PubMed]
22. Das, S.; Das, D.K. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Target 2007, 6, 168-173. [CrossRef]
23. Rubiolo, J.A.; Mithieux, G.; Vega, F.V. Resveratrol protects primary rat hepatocytes against oxidative stress damage: Activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur. J. Pharmacol. 2008, 591, 66-72. [CrossRef] [PubMed]
24. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506. [CrossRef] [PubMed]
25. Fauconneau, B.; Waffo-Teguo, P.; Huguet, F.; Barrier, L.; Decendit, A.; Merillon, J.M. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci. 1997, 61, 2103-2110. [CrossRef]
26. Jang, D.S.; Kang, B.S.; Ryu, S.Y.; Chang, I.M.; Min, K.R.; Kim, Y. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem. Pharmacol. 1999, 57, 705-712. [CrossRef]
27. Saiko, P.; Szakmary, A.; Jaeger,W.; Szekeres, T. Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res. 2008, 658, 68-94. [CrossRef] [PubMed]
28. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 2004, 24, 2783-2840. [PubMed]
29. Daroch, F.; Hoeneisen, M.; González, C.L.; Kawaguchi, F.; Salgado, F.; Solar, H.; García, A. In vitro antibacterial activity of Chilean red wines against Helicobacter pylori. Microbios 2001, 104, 79-85. [PubMed]
30. Martini, S.; Bonechi, C.; Rossi, C.; Figura, N. Increased susceptibility to resveratrol of Helicobacter pylori strains isolated from patients with gastric carcinoma. J. Nat. Prod. 2011, 74, 2257-2260. [CrossRef] [PubMed]
31. Paulo, L.; Oleastro, M.; Gallardo, E.; Queiroz, J.A.; Domingues, F. Anti-Helicobacter pylori and urease inhibitory activities of resveratrol and red wine. Food. Res. Int. 2011, 44, 964-969. [CrossRef]
32. Smoot, D.T.; Elliott, T.B.; Verspaget, H.W.; Jones, D.; Allen, C.R.; Vernon, K.G.; Bremner, T.; Kidd, L.C.; Kim, K.S.; Groupman, J.D.; et al. Influence of Helicobacter pylori on reactive oxygen-induced gastric epithelial cell injury. Carcinogenesis 2000, 21, 2091-2095. [CrossRef] [PubMed]
33. Wilson, K.T.; Ramanujam, K.S.; Mobley, H.L.; Musselman, R.F.; James, S.P.; Meltzer, S.J. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. Gastroenterology 1996, 111, 1524-1533. [CrossRef]
34. Katsurahara, M.; Kobayashi, Y.; Iwasa, M.; Ma, N.; Inoue, H.; Fujita, N.; Tanaka, K.; Horiki, N.; Gabazza, E.C.; Takei, Y. Reactive nitrogen species mediate DNA damage in Helicobacter pylori-infected gastric mucosa. Helicobacter 2009, 14, 552-558. [CrossRef] [PubMed]
35. Finkel, T. Signal transduction by reactive oxygen species. J. Cell Biol. 2011, 194, 7-15. [CrossRef] [PubMed]
36. Kregel, K.C.; Zhang, H.J. An integrated view of oxidative stress in aging: Basic mechanisms, functional effects, and pathological considerations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292, R18-R36. [CrossRef] [PubMed]
37. Drake, I.M.; Mapstone, N.P.; Schorah, C.J.; White, K.L.; Chalmers, D.M.; Dixon, M.F.; Axon, A.T. Reactive oxygen species activity and lipid peroxidation in Helicobacter pylori associated gastritis: Relation to gastric mucosal ascorbic acid concentrations and effect of H. pylori eradication. Gut 1998, 42, 768-771. [CrossRef] [PubMed]
38. Suzuki, H.; Mori, M.; Seto, K.; Kai, A.; Kawaguchi, C.; Suzuki, M.; Suematsu, M.; Yoneta, T.; Miura, S.; Ishii, H. Helicobacter pylori-associated gastric pro- and antioxidant formation in Mongolian gerbils. Free Radic. Biol. Med. 1999, 26, 679-684. [CrossRef]
39. Mai, U.E.H.; Perez-Perez, G.I.; Allen, J.B.; Wahl, S.M.; Blaser, M.J.; Smith, P.D. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J. Exp. Med. 1992, 175, 517-525. [CrossRef] [PubMed]
40. Craig, P.M.; Territo, M.C.; Karnes, W.E.; Walsh, J.H. Helicobacter pylori secretes a chemotactic factor monocytes and neutrophils. Gut 1992, 33, 1020-1023. [CrossRef] [PubMed]
41. Krawisz, J.E.; Sharon, P.; Stenson, W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87, 1344-1350. [PubMed]
42. Bishayee, A.; Dhir, N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: Inhibition of cell proliferation and induction of apoptosis. Chem. Biol. Interact. 2009, 179, 131-144. [CrossRef] [PubMed]
43. Zhang, X.L.; Jiang, A.M.; Ma, Z.Y.; Li, X.B.; Xiong, Y.Y.; Dou, J.F.; Wang, J.F. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-Helicobacter pylori activity in vitro and in vivo. Molecules 2015, 20, 3972-3985. [CrossRef] [PubMed]
44. Guy, B.; Hessler, C.; Fourage, S.; Haensler, J.; Vialon-Lafay, E.; Rokbi, B. Systemic immuniza- tion with urease protects mice against Helicobacter pylori infection. Vaccine 1998, 16, 850-856. [CrossRef]
45. Ohkawa, H.; Ohnishi, N.; Yagi, K. Assay for lipid peroxides for animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351-358. [CrossRef]
46. Wu, Y.H.; Zang, X.; Wang, D.H. Role of asymmetric dimethylarginine in acute lung injury induced by cerebral ischemia/reperfusion injury in rats. J. South. Med. Univ. 2011, 31, 1289-1293.